PDF(Pubmed)
Abstract：
UNASSIGNED: To investigate the clinical value of combined detection of carcinoembryonic antigen(CEA) and CA125 in the diagnosis of non-small cell lung cancer(NSCLC) combined with malignant pleural effusion.
UNASSIGNED: This was retrospective research. Fifty-six NSCLC patients combined with malignant pleural effusion in Baoding No.1 Hospital, China, from January 2020 to January 2022 were recruited as the malignant group, and another 56 NSCLC patients combined with pleural effusion in the same period were recruited as the benign group. Pleural effusion and serum specimens were collected from both groups and their carcinoembryonic antigen (CEA), carbohydrate antigen 125(CA125) and SP70 antigen levels were measured respectively. The differences in index levels between the two groups were compared, and the value of the index in diagnosing NSCLC combined with malignant pleural effusion was analyzed.
UNASSIGNED: The positive rates of CEA, CA125 and SP70 antigen in pleural effusion were higher in the malignant group than in the benign group (p>0.05); The positive rates of CEA and CA125 in the malignant group were higher than those in the benign group (p>0.05), with no statistically significant difference between the two groups in the positive rates of SP70 antigen (p>0.05). ROC curve analysis revealed the value of serum CEA and CA12 in the diagnosis of NSCLC combined with malignant pleural effusion, while serum SP70 antigen had no diagnostic value (p>0.05).
UNASSIGNED: The combined detection of CEA, CA125 and SP70 antigen boasts a higher diagnostic value for NSCLC-mediated pleural effusion, with higher diagnostic value than the combined detection of serum indexes.
UNASSIGNED: This was retrospective research. Fifty-six NSCLC patients combined with malignant pleural effusion in Baoding No.1 Hospital, China, from January 2020 to January 2022 were recruited as the malignant group, and another 56 NSCLC patients combined with pleural effusion in the same period were recruited as the benign group. Pleural effusion and serum specimens were collected from both groups and their carcinoembryonic antigen (CEA), carbohydrate antigen 125(CA125) and SP70 antigen levels were measured respectively. The differences in index levels between the two groups were compared, and the value of the index in diagnosing NSCLC combined with malignant pleural effusion was analyzed.
UNASSIGNED: The positive rates of CEA, CA125 and SP70 antigen in pleural effusion were higher in the malignant group than in the benign group (p>0.05); The positive rates of CEA and CA125 in the malignant group were higher than those in the benign group (p>0.05), with no statistically significant difference between the two groups in the positive rates of SP70 antigen (p>0.05). ROC curve analysis revealed the value of serum CEA and CA12 in the diagnosis of NSCLC combined with malignant pleural effusion, while serum SP70 antigen had no diagnostic value (p>0.05).
UNASSIGNED: The combined detection of CEA, CA125 and SP70 antigen boasts a higher diagnostic value for NSCLC-mediated pleural effusion, with higher diagnostic value than the combined detection of serum indexes.
摘要：
■探讨联合检测癌胚抗原(CEA)和CA125对非小细胞肺癌(NSCLC)合并恶性胸腔积液的诊断价值。
■这是回顾性研究。保定市第一医院非小细胞肺癌合并恶性胸腔积液56例，中国,从2020年1月到2022年1月被招募为恶性组，另纳入同期56例NSCLC合并胸腔积液患者作为良性组。收集两组的胸腔积液和血清标本及其癌胚抗原（CEA），分别检测糖类抗原125(CA125)和SP70抗原水平。比较两组指标水平的差异,分析该指标对NSCLC合并恶性胸腔积液的诊断价值。
■CEA的阳性率，恶性组胸腔积液中CA125和SP70抗原高于良性组(p>0.05);恶性组胸腔积液中CEA和CA125的阳性率高于良性组(p>0.05),两组SP70抗原阳性率差异无统计学意义(p>0.05)。ROC曲线分析显示血清CEA和CA12在非小细胞肺癌合并恶性胸腔积液诊断中的价值,血清SP70抗原无诊断价值(p>0.05)。
■CEA的联合检测，CA125和SP70抗原对NSCLC介导的胸腔积液具有较高的诊断价值，血清指标联合检测具有较高的诊断价值。
■这是回顾性研究。保定市第一医院非小细胞肺癌合并恶性胸腔积液56例，中国,从2020年1月到2022年1月被招募为恶性组，另纳入同期56例NSCLC合并胸腔积液患者作为良性组。收集两组的胸腔积液和血清标本及其癌胚抗原（CEA），分别检测糖类抗原125(CA125)和SP70抗原水平。比较两组指标水平的差异,分析该指标对NSCLC合并恶性胸腔积液的诊断价值。
■CEA的阳性率，恶性组胸腔积液中CA125和SP70抗原高于良性组(p>0.05);恶性组胸腔积液中CEA和CA125的阳性率高于良性组(p>0.05),两组SP70抗原阳性率差异无统计学意义(p>0.05)。ROC曲线分析显示血清CEA和CA12在非小细胞肺癌合并恶性胸腔积液诊断中的价值,血清SP70抗原无诊断价值(p>0.05)。
■CEA的联合检测，CA125和SP70抗原对NSCLC介导的胸腔积液具有较高的诊断价值，血清指标联合检测具有较高的诊断价值。
